Zipf T - Search Results

1

Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients.

Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, Culbert SJ, Danielson M, Jeha SS, Kuttesch JF, Rolston KV. Mullen CA, et al. Among authors: zipf t. Cancer. 1999 Jul 1;86(1):126-34. Cancer. 1999. PMID: 10391572 Clinical Trial.

2

Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer.

Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, Culbert SJ, Danielson M, Jeha SS, Kuttesch JF, Rolston KV. Mullen CA, et al. Among authors: zipf t. J Pediatr Hematol Oncol. 1999 May-Jun;21(3):212-8. doi: 10.1097/00043426-199905000-00009. J Pediatr Hematol Oncol. 1999. PMID: 10363854 Clinical Trial.

3

High-dose mercaptopurine and intermediate-dose cytarabine during first remission of acute myeloid leukemia.

Canpolat C, Jeha S, Lockhart S, Ramirez I, Zipf T, Pinkel D. Canpolat C, et al. Among authors: zipf t. Cancer Invest. 1997;15(2):121-6. doi: 10.3109/07357909709115764. Cancer Invest. 1997. PMID: 9095207 Clinical Trial.

4

Acute reversible arthropathy in a pediatric patient with cancer treated with a short course of ciprofloxacin for febrile neutropenia.

Mullen CA, Petropoulos D, Rytting M, Jeha S, Zipf T, Roberts WM, Rolston KV. Mullen CA, et al. Among authors: zipf t. J Pediatr Hematol Oncol. 1998 Sep-Oct;20(5):516-7. doi: 10.1097/00043426-199809000-00026. J Pediatr Hematol Oncol. 1998. PMID: 9787333 No abstract available.

5

Detection of minimal residual disease in all: biology, methods, and applications.

Roberts WM, Estrov Z, Kitchingman GR, Zipf TF. Roberts WM, et al. Among authors: zipf tf. Cancer Treat Res. 1996;84:149-66. doi: 10.1007/978-1-4613-1261-1_8. Cancer Treat Res. 1996. PMID: 8724630 Review.

6

High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.

Lockhart S, Plunkett W, Jeha S, Ramirez I, Zipf T, Cork A, Pinkel D. Lockhart S, et al. Among authors: zipf t. J Clin Oncol. 1994 Mar;12(3):587-95. doi: 10.1200/JCO.1994.12.3.587. J Clin Oncol. 1994. PMID: 8120558 Clinical Trial.

7

Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia.

Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Roberts WM, et al. Among authors: zipf tf. N Engl J Med. 1997 Jan 30;336(5):317-23. doi: 10.1056/NEJM199701303360501. N Engl J Med. 1997. PMID: 9011783 Free article.

8

Monitoring residual disease in acute lymphoblastic leukemia: therapeutic implications.

Roberts WM, Zipf TF, Kitchingman GR, Tubergen DG, Estrov Z. Roberts WM, et al. Among authors: zipf tf. Cytokines Mol Ther. 1995 Mar;1(1):65-9. Cytokines Mol Ther. 1995. PMID: 9384665 Review.

9

The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences.

Roberts WM, Estrov Z, Kitchingman GR, Zipf TF. Roberts WM, et al. Among authors: zipf tf. Leuk Lymphoma. 1996 Jan;20(3-4):181-97. doi: 10.3109/10428199609051607. Leuk Lymphoma. 1996. PMID: 8624456 Review.

10

Minocycline-ethylenediaminetetraacetate lock solution for the prevention of implantable port infections in children with cancer.

Chatzinikolaou I, Zipf TF, Hanna H, Umphrey J, Roberts WM, Sherertz R, Hachem R, Raad I. Chatzinikolaou I, et al. Among authors: zipf tf. Clin Infect Dis. 2003 Jan 1;36(1):116-9. doi: 10.1086/344952. Epub 2002 Dec 11. Clin Infect Dis. 2003. PMID: 12491212 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Search Page

Filters